

DHU-Imaging: Molecular Imaging & Imaging-Guided Therapy

Mylène SEUX (Project Manager, mylene.seux@ap-hm.fr), Stefan ENOCH and Alexis JACQUIER (Deputy Directors) & Eric GUEDJ (Director)

Keywords : molecular imaging, interventional radiology, imaging agents, instrumentation, image processing

Abstract: *Départements Hospito-Universitaires* (DHU) are *Projects of excellence* whose objective is to be the support of joint projects between the hospital, universities and research organizations. **DHU-Imaging** is one of the 5 DHUs chosen by the A*MIDEX Foundation, with the support of AMU, AP-HM, CNRS, Ecole Centrale Marseille and CEA. **DHU-Imaging** associates 13 hospital departments, 28 academic laboratories, 10 technology platforms including CERIMED (European Center for Research in MEDical Imaging), 12 industrial partners, and is supported by 2 clusters (Eurobiomed and OPTITEC) and by patients' associations.

The issue of **DHU-Imaging** consists in selective deposit of a physical agent on a biological target (*vector-based*), using :

- > **molecular tracers**, mainly detected by isotopic labeling (preclinical and clinical imaging) and/or optical (subcellular, preclinical and tissue imaging) for multiscale imaging biomarkers and theranostics
- > **interventional percutaneous or endovascular procedures** for imaging-guided therapy

These applications are mainly conducted in:

- > **Oncology**, with the two Comprehensive Cancer Centers of APHM (Brain Tumor Program and Pancreatic Tumor Program), and an emerging topic (endocrine tumors)
- > **Clinical Neuroscience** (psychiatry, neurology, ophthalmology, chronic pain diseases)


Aim 1

Precise and early characterization of disease (diagnostic, molecular signature, biomarkers) because :

- > molecular changes precede morphological ones:
more sensitive for early diagnosis & evaluation




Evaluation of Alzheimer's Disease by PET amyloid imaging



Evaluation of Alzheimer's Disease by PET TAU imaging

- > molecular **biomarkers** better evaluate complexity of each disease at patient- and lesion- levels: **more specific for precise diagnosis & evaluation**




Molecular signature of neuro-endocrine tumors

Aim 2

Personalized treatment : selective deposit of a physical agent on a biological target (*vector-based*), using


- > **interventional percutaneous or endovascular procedures**
- > **molecular theranostics**




Aim 3

Evaluation of efficiency of treatment

- > to not delay more effective treatment, and not cause unnecessary side effects



Therapeutic evaluation of encephalitis by 18FDG-PET




18FDG-PET predicts prognostic after 1 cycle of chemotherapy in lymphoma

A quantitative imaging to characterize molecular signatures

Understand, Diagnose, Select, Predict, Evaluate, Treat

Biomarker	Companion Drug	Theranostic
Neuroscience ✓ GLUT1 ✓ Cerebral blood flow ✓ Dopamine transporter ✓ DOPA-decarboxylase ✓ D2/3 ✓ Noradrenergic reuptake ✓ 5HT1-A ✓ Acetylcholinesterase ✓ NMDA receptor ✓ TSPO: microglia activation ✓ Amyloid burden ✓ TAU phosphorylation	Oncology ✓ GLUT1 ✓ LAT1 ✓ Choline-kinase ✓ PSMA ✓ Tyrosine ✓ Somatostatin receptor ✓ Fluor ✓ VCAM-1 ✓ Thymidine-kinase ✓ Hypoxia	Oncology/Neuroscience ✓ Targeted therapy ✓ Anti-amyloid ✓ Anti-TAU ✓ Anti-inflammatory ✓ DOPA
Extended to : ✓ NOTES ✓ TMS/DBS ✓ Radiosurgery ✓ CBT ✓ Virtual Reality Exposure Therapy		
Gallium, for tailored peptide labeling		



Aim 4

Technology Development mainly in :

- > **Instrumentation**
- > **Image processing**



$$SUV_{mean} = \frac{C_{mean}(kBq/ml)}{A_{eq}(kBq)/W(gr)}$$

$$SUV_{max} = \frac{C_{max}(kBq/ml)}{A_{eq}(kBq)/W(gr)}$$

$$SUV_{peak} = \frac{C_{mean-peak}(kBq/ml)}{A_{eq}(kBq)/W(gr)}$$